Selegiline for Parkinson's disease

Abstract

Monoamine oxidase inhibitors that have been available in the United States are nonselective and thus act equally on peripheral and brain monoamine oxidase. Recently, selegiline, a selective monoamine oxidase inhibitor, has been approved for use in the management of Parkinson's disease. Clinical trials demonstrate that selegiline in combination with carbidopa/levodopa is effective in relieving symptoms and prolonging remission. The dosage of carbidopa/levodopa can usually be reduced, resulting in diminished side effects. Selegiline is relatively nontoxic and appears to be a valuable addition in the management of Parkinson's disease.